Analytical Data
-
Gene name
CHRNb1
- Application
-
Alternative Names
CHRNb1；ACHRB；CHRNB；Acetylcholine receptor subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11230
-
Expression Region
24-244aa
-
AA Sequence
SEAEGRLREKLFSGYDSSVRPAREVGDRVRVSVGLILAQLISLNEKDEEMSTKVYLDLEWTDYRLSWDPAEHDGIDSLRITAESVWLPDVVLLNNNDGNFDVALDISVVVSSDGSVRWQPPGIYRSSCSIQVTYFPFDWQNCTMVFSSYSYDSSEVSLQTGLGPDGQGHQEIHIHEGTFIENGQWEIIHKPSRLIQPPGDPRGGREGQRQEVIFYLIIRRK
-
Molecular Weight
32 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHRNb1, or the nicotinic acetylcholine receptor subunit beta 1, is a crucial component of the nicotinic acetylcholine receptor (nAChR) complex, which plays a fundamental role in synaptic transmission and neuromuscular junction function. Research on CHRNb1 is primarily driven by its implications in various neurological disorders, including Alzheimer's disease, schizophrenia, and nicotine dependence. Given that nAChRs are implicated in cognitive processes and neuroplasticity, understanding the structure and function of CHRNb1 could provide insights into therapeutic targets for these conditions. The recombinant expression of CHRNb1 protein allows researchers to study its biophysical properties, interactions with other receptor subunits, and the influence of specific ligands. This involves the production of CHRNb1 in host systems, such as bacteria or mammalian cells, facilitating detailed investigations into its functional roles and mechanisms. Furthermore, studying CHRNb1 at the molecular level enhances our understanding of receptor assembly and signaling pathways, which is essential for developing novel pharmacological interventions. Overall, the exploration of CHRNb1 recombinant proteins remains a vibrant area of research, with the potential to unveil new therapeutic avenues for neurodegenerative and psychiatric disorders.
